Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Saccharin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saccharin SCHEMBL29364573 | 1.00 | GPR3 (0.43) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL485938 | 1.00 | GPR3 (0.43) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL3372 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL29355014 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL787894 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL10399957 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL473608 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL2954783 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL10618576 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL5870938 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111411379-B | Low-stress nickel-phosphorus alloy roller for microstructure machining and electroplating process thereof | 常州华威新材料有限公司 | 2021-09-21 | — | — | CN | claimed |
| CN-113230220-A | Preparation method of pregabalin | 大桐制药（中国）有限责任公司 | 2021-08-10 | — | — | CN | claimed |
| CN-111411379-A | Low-stress nickel-phosphorus alloy roller for microstructure machining and electroplating process thereof | 常州华威新材料有限公司 | 2020-07-14 | — | — | CN | claimed |
| CN-122055143-A | Solid compositions containing bromhexine | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| EP-4676444-A1 | NANOPARTICLE FORMULATIONS FOR A NON-OPIOID DRUG | South Rampart Pharma (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025100523-A1 | METHOD FOR PRODUCING SOLID PREPARATION, AND TABLETS | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20250143991-A1 | SULFATE-BASED SURFACTANT FREE ORAL CARE COMPOSITION WITH IMPROVED LOW TEMPERATURE STABILITY | KOLMAR KOREA CO., LTD. (KR) | 2025-05-08 | — | — | US | disclosed |
| EP-4529923-A1 | GEL COATING AND ORAL SOLID COMPOSITION | Kyowa Pharmaceutical Industry Co., Ltd. (JP) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024191741-A1 | NANOPARTICLE FORMULATIONS FOR A NON-OPIOID DRUG | SOUTH RAMPART PHARMA (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240307314-A1 | GEL FILM AND ORAL SOLID COMPOSITION | KYOWA PHARMACEUTICAL INDUSTRY CO., LTD. (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-118265526-A | Pharmaceutical composition | 玛路弘株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-20110167506-A1 | METHOD FOR EVALUATION OF DEVELOPMENTAL TOXICITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2302050-A1 | METHOD FOR EVALUATION OF DEVELOPMENTAL TOXICITY | Sumitomo Chemical Company, Limited (JP) | 2011-03-30 | — | — | EP | disclosed |
| EP-2177646-B1 | Stress-reduced Ni-P/Pd stacks for bondable wafer surfaces | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| EP-2038215-B1 | PROCESS FOR THE PRODUCTION OF HYDROGEN PEROXIDE | AKZO NOBEL NV (NL) | 2011-02-23 | — | — | EP | disclosed |
| EP-2197452-A1 | DHEAS INHALATION COMPOSITIONS | Epigenesis Pharmaceutical, LLC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20090118249-A1 | DHEAS INHALATION COMPOSITIONS | EPIGENESIS PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2009032955-A1 | DHEAS INHALATION COMPOSITIONS | EPIGENESIS PHARMACEUTICALS, LLC (US) | 2009-03-12 | — | — | WO | disclosed |
| US-6340664-B1 | FOR WASHING TEXTILES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (KGAA) (DE) | 2002-01-22 | — | — | US | disclosed |